Additional term of agreement renewable upon mutual agreement.

No definition available.

Name:	nk_AdditionalTermOfAgreementRenewableUponMutualAgreement
Namespace Prefix:	nk_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Licensing agreement.

+ References

No definition available.

+ Details

Name:	nk_LicensingAgreementLineItems
Namespace Prefix:	nk_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Maximum number of patients in phase one and two for clinical trials.

+ References

No definition available.

+ Details

Name:	nk_MaximumNumberOfPatientsInPhaseOneAndTwoForClinicalTrials
Namespace Prefix:	nk_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Operating and capital expenditures incurred but not yet paid.

+ References

No definition available.

+ Details

Name:	nk_OperatingAndCapitalExpendituresIncurredButNotYetPaid
Namespace Prefix:	nk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Related party agreement renewal term.

+ References

No definition available.

+ Details

Name:	nk_RelatedPartyAgreementRenewalTerm
Namespace Prefix:	nk_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Supplies and milestone charges for conducting clinical trials.

+ References

No definition available.

+ Details

Name:	nk_SuppliesAndMilestoneChargesForConductingClinicalTrials
Namespace Prefix:	nk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Term of agreement.

+ References

No definition available.

+ Details

Name:	nk_TermOfAgreement
Namespace Prefix:	nk_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

+ Details

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(11))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3)(a)(2))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

+ Details

Name:	us-gaap_DueFromRelatedPartiesCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name:	us-gaap_OperatingExpenses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireProductiveAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=nk_JointDevelopmentAgreementForCOVID19Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=nk_EstimatedPersonnelCostsLaboratorySuppliesAndOtherExpensesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=nk_ImmunityBioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nk_COVIDJointDevelopmentAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=nk_AltorBioScienceCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration and License Agreements - Additional Information (Detail)	1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2020 USD ($) Patient	Jun. 30, 2019 USD ($)	Dec. 31, 2019 USD ($)
Licensing Agreement [Line Items]
Operating expenses		$ 20,228,000	$ 17,313,000	$ 38,835,000	$ 35,653,000
Research and development (including amounts with related parties)		13,709,000	13,131,000	26,943,000	25,729,000
Due from related parties		26,000		26,000		$ 47,000
Joint Development Agreement for COVID 19
Licensing Agreement [Line Items]
Capital expenditures for laboratory equipment				2,300,000
Operating and capital expenditures				$ 4,500,000
Term of agreement				5 years
Additional term of agreement renewable upon mutual agreement				5 years
Joint Development Agreement for COVID 19 \| Sales
Licensing Agreement [Line Items]
Profit sharing percentage				60.00%
Joint Development Agreement for COVID 19 \| Estimated Personnel Costs, Laboratory Supplies, and Other Expenses
Licensing Agreement [Line Items]
Operating expenses				$ 5,400,000
ImmunityBio
Licensing Agreement [Line Items]
Related party, agreement renewal term	1 year
Research and development (including amounts with related parties)		100,000	5,000	$ 100,000	100,000
ImmunityBio \| Joint Development Agreement for COVID 19 \| Sales
Licensing Agreement [Line Items]
Profit sharing percentage				40.00%
ImmunityBio \| Collaborative Arrangement
Licensing Agreement [Line Items]
Related party, agreement renewal term	1 year
Research and development (including amounts with related parties)		29,700		$ 100,000
ImmunityBio \| Collaborative Arrangement \| Prepaid Expenses and Other Current Assets
Licensing Agreement [Line Items]
Due from related parties		29,700		29,700
ImmunityBio \| COVID Joint Development Agreement
Licensing Agreement [Line Items]
Research and development (including amounts with related parties)		29,700		100,000
ImmunityBio \| COVID Joint Development Agreement \| Prepaid Expenses and Other Current Assets
Licensing Agreement [Line Items]
Due from related parties		29,700		$ 29,700
Altor
Licensing Agreement [Line Items]
Maximum number of patients in phase 1 and 2 for clinical trials \| Patient				400
Supplies and milestone charges for conducting clinical trials		$ 0	$ 0	$ 0	$ 0